Scientists detected the receptor tyrosine kinase activity in gefitinib-resistant colorectal cancer cells, pan-erb-b2 receptor tyrosine kinase 3 (ErbB3)/EGFR was significantly activated and provided a potential multi-ErbB treatment target.
[Cell Death & Disease]
Sorry, but the selected Zotpress account can't be found.
